We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Big Rock Partners Acquisition Corporation | NASDAQ:BRPA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.25 | 23.12 | 23.68 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 6, 2023
NRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38302 | 82-2844431 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
1201 Orange Street, Suite 600 Wilmington, Delaware |
19801 | |
(Address of principal executive offices) | (Zip Code) |
(484) 254-6134
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.001 per share | NRXP | The Nasdaq Stock Market LLC | ||
Warrants to purchase one share of Common Stock | NRXPW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
This Amendment No. 1 (the “Amendment”) to the Registrant’s Current Report on Form 8-K filed on June 6, 2023 (the “Original Report”) is being filed to (i) amend and restate Item 1.01 and (i) to add Item 3.02, which incorporates certain information contained in Item 1.01. Except as described above, this Amendment does not amend, update or change any other disclosures in the Original Report. In addition, the information contained in this Amendment does not reflect events occurring after the filing of the Original Report and does not modify or update the disclosures therein, except as specifically identified above.
Item 1.01. Entry into a Material Definitive Agreement.
On June 6, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the purchasers signatory thereto (the “Investors”), providing for the issuance and sale of 9,670,002 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 9,670,002 shares of Common Stock (the “Investor Warrants”) (or pre-funded warrants in lieu thereof). The Common Stock will be issued in a registered direct offering for a purchase price of $0.65 per share (the “Offering”) and the Investor Warrants will be offered pursuant to a private placement under Section 4(a)(2) of the Securities Act. No pre-funded warrants in lieu of Common Stock were issued. The Investor Warrants will have an exercise price of $0.6525 per share, will be initially exercisable beginning six months following the date of issuance (the “Initial Exercise Date”) and will expire five and one half years from the date of issuance.. The aggregate gross proceeds to the Company from the Offering are expected to be approximately $6.28 million. The Company intends to use the net proceeds from such offering to initiate research into the use of NRX-101 for the treatment of PTSD and Chronic Pain. In connection with this offering, the company anticipates servicing its current debt on a current-interest basis through the end of 2023 in order to devote maximum available capital to the advancement of its pharmaceutical assets.
Jonathan Javitt, Director and Chief Scientist, and Daniel Javitt, the brother of Jonathan Javitt, and entities controlled by them, have entered into a customary lock-up agreement (the “Lock-Up Agreement”) with the Company providing that each will not transfer shares of Common Stock and certain other securities held by them for a period of 60 days following the closing of the Offering.
The closing of the sale of these securities is expected to take place on or about June 8, 2023, subject to customary closing conditions.
In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain Investors to amend certain existing warrants to purchase up to 9,622,778 shares of Common Stock that were previously issued in August 2021 and February 2022 to the Investors, with an exercise price of $3.07 and $12.00 per share, respectively (the “Amended Warrants”) as follows: (i) lower the exercise price of the Amended Warrants to $0.6525 per share, and (ii) provide that the Amended Warrants, as amended, will not be exercisable until six months following the closing date of the registered direct offering, and (iii) extend the original expiration date of the Amended Warrants so that they will terminate five and one half years from the closing of the offering.
H.C. Wainwright & Co. LLC is acting as the exclusive placement agent (the “Placement Agent”) for the Offering, pursuant to a letter agreement dated June 3, 2023 (the “Engagement Letter”). The Common Stock is being issued pursuant to the Company’s registration statement on Form S-3 filed with the SEC on June 9, 2022 (File No. 333-265492) and which became effective on June 21, 2022. The offering of the Common Stock to be issued in the Offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available at the SEC’s website located at http://www.sec.gov.
The Placement Agent did not purchase or sell any securities, nor is it required to arrange the purchase or sale of any minimum number or dollar amount of securities. The Placement Agent agreed to use its reasonable best efforts to arrange for the sale of all of the securities being offered in the Offering. The Placement Agent will be paid a cash fee equal to 6.5% of the gross proceeds received by the Company from the sale of the securities at the closing of the Offering. In addition, the Placement Agent will also be issued warrants to purchase that number of Shares of the Company equal to 2.0% of the aggregate number of Common Stock placed in the Offering (the “Placement Agent Warrants”) pursuant to a private placement under Section 4(a)(2). The Placement Agent also receive reimbursement of certain of its expenses. Under the Engagement Letter, in the event the Company or any of its subsidiaries raises funds in a public offering or private placement, subject to the consummation of the Offering within forty-five days from June 3, 2023 and until six months thereafter, the Placement Agent will have the right to act as lead left joint book-running manager or lead left placement agent for such financing, subject to certain limitations contained in the Engagement Letter.
The foregoing description of the Investor Warrants, Warrant Amendment Agreement, Securities Purchase Agreement and Lock-Up Agreement, do not purport to be complete and are qualified in their entirety by the full text of the form of Investor Warrants, form of Warrant Amendment Agreement, form of Securities Purchase Agreement and the Lock-Up Agreement attached hereto as Exhibits 4.1, 4.2, 10.1 and 10.2, respectively.
Item 3.02 Unregistered Sales of Equity Securities
The information disclosed under Item 1.01 of this Current Report is incorporated herein by reference.
The issuance of the Amended Warrants, the Investor Warrants and the Placement Agent Warrants are being offered and sold in a transaction exempt from registration under Section 4(a)(2) of the Securities Act.
Item 7.01. Regulation FD Disclosure.
On June 6, 2023, the Company issued a press release announcing its entrance into the Securities Purchase Agreement and the transactions contemplated thereby. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No. |
Description | |
4.1 | Form of Investor Warrant | |
4.2 | Form of Warrant Amendment Agreement | |
5.1 | Opinion of Kirkland & Ellis LLP | |
10.1 | Form of Securities Purchase Agreement | |
10.2 | Lock-Up Agreement | |
99.1 | Press Release, dated June 6, 2023 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NRX PHARMACEUTICALS, INC. | ||
Date: June 7, 2023 | By: | /s/ Stephen Willard |
Name: | Stephen Willard | |
Title: | Chief Executive Officer and Acting General Counsel |
1 Year Big Rock Partners Acquis... Chart |
1 Month Big Rock Partners Acquis... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions